RETA earnings call for the period ending September 30, 2019.
News & Analysis: Reata Pharmaceuticals, Inc.
A drug trial showed promise in treating a particularly stubborn disease.
Keeping up with the news from major medical meetings has become a requirement for healthcare investors.
The company reclaimed rights to several promising drug candidates last week; this week, positive data from a pivotal clinical trial sent it soaring.
Earnings results and favorable comments lifted several stocks.
Data from a phase 2 study looks promising.
RETA earnings call for the period ending June 30, 2019.
RETA earnings call for the period ending March 31, 2019.
RETA earnings call for the period ending December 31, 2018.
A drug targeting a rare form of chronic kidney disease is fueling investor's optimism.